Press release
Hypercholesterolemia Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight
Hypercholesterolemia Clinical Trials
"Hypercholesterolemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypercholesterolemia Market.
The Hypercholesterolemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample page @ https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Hypercholesterolemia Pipeline Report:
• Companies across the globe are diligently working toward developing novel Hypercholesterolemia treatment therapies with a considerable amount of success over the years.
• Hypercholesterolemia companies working in the treatment market are EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merck Sharp & Dohme LLC, Haisco Pharmaceutical Group Co., Ltd., Akeso Biopharma, Addpharma Inc., Jiangsu HengRui Medicine Co., Ltd., and others, are developing therapies for the Hypercholesterolemia treatment
• Emerging Hypercholesterolemia therapies in the different phases of clinical trials are- EPIC-221, AMTX 100, Research programme: epigenetic editors, VERVE-101, VXX-401, ARO-ANG 3, MK-0616, HSK31679, Ebronucimab, AD-221, SHR-1209, and others are expected to have a significant impact on the Hypercholesterolemia market in the coming years.
• In November 2024, The Dutch late-stage clinical biopharma company, NewAmsterdam, has announced promising topline results from its Phase III TANDEM trial, evaluating the cholesterol-lowering potential of its combination therapy, obicetrapib. This treatment targets individuals with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).
• In July 2024, NewAmsterdam Pharma has successfully enrolled 407 patients in the pivotal Phase III TANDEM trial, which is evaluating obicetrapib combined with ezetimibe in patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD). Obicetrapib has shown excellent tolerability in over 800 patients with elevated lipid levels during NewAmsterdam's clinical trials. As a result, obicetrapib has the potential to become the first cholesteryl ester transfer protein (CETP) inhibitor to reach clinical practice.
Hypercholesterolemia Overview
Hypercholesterolemia refers to an abnormally high level of cholesterol in the blood, a condition that can significantly increase the risk of cardiovascular diseases, including heart attacks and strokes. Cholesterol is a fatty substance necessary for building cells and producing certain hormones, but excessive amounts, especially low-density lipoprotein (LDL) cholesterol-often called "bad" cholesterol-can lead to plaque buildup in the arteries. This buildup narrows and hardens the arteries, restricting blood flow.
The condition can be inherited (familial hypercholesterolemia) or acquired through lifestyle factors, including poor diet, lack of physical activity, smoking, and obesity. Inherited forms typically result in high cholesterol levels from a young age and are often more severe.
Symptoms of hypercholesterolemia are not typically visible, but over time, it can cause atherosclerosis and lead to symptoms of heart disease. Diagnosis involves blood tests to measure cholesterol levels. Treatment focuses on lifestyle changes, such as diet and exercise, alongside medications like statins to lower cholesterol. Early detection and management are key in preventing complications. Regular screening is recommended for individuals with a family history of high cholesterol or heart disease.
Get a Free Sample PDF Report to know more about Hypercholesterolemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Hypercholesterolemia Drugs Under Different Phases of Clinical Development Include:
• EPIC-221: EPIC BIO
• AMTX 100: Amytrx Therapeutics
• Research programme: epigenetic editors: Chroma Medicine
• VERVE-101: Verve Therapeutics, Inc
• VXX-401: Vaxxinity, Inc
• ARO-ANG 3: Arrowhead Pharmaceuticals
• MK-0616: Merck Sharp & Dohme LLC
• HSK31679: Haisco Pharmaceutical Group Co., Ltd.
• Ebronucimab: Akeso Biopharma
• AD-221: Addpharma Inc.
• SHR-1209: Jiangsu HengRui Medicine Co., Ltd.
Hypercholesterolemia Pipeline Therapeutics Assessment
• Hypercholesterolemia Assessment by Product Type
• Hypercholesterolemia By Stage and Product Type
• Hypercholesterolemia Assessment by Route of Administration
• Hypercholesterolemia By Stage and Route of Administration
• Hypercholesterolemia Assessment by Molecule Type
• Hypercholesterolemia by Stage and Molecule Type
DelveInsight's Hypercholesterolemia Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Hypercholesterolemia product details are provided in the report. Download the Hypercholesterolemia pipeline report to learn more about the emerging Hypercholesterolemia therapies at:
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Hypercholesterolemia Therapeutics Market include:
Key companies developing therapies for Hypercholesterolemia are - Regeneron Pharmaceuticals Inc, Verve Therapeutics Inc, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Huons Co Ltd, LipimetiX Development Inc, Novartis AG, Nyrada Inc, Addpharma Inc, and others.
Hypercholesterolemia Pipeline Analysis:
The Hypercholesterolemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hypercholesterolemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypercholesterolemia Treatment.
• Hypercholesterolemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypercholesterolemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hypercholesterolemia drugs and therapies-
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hypercholesterolemia Pipeline Market Drivers
• Increase in prevalence of Hypercholesterolemia, rising number of clinical studies for the treatment of Hypercholesterolemia are some of the important factors that are fueling the Hypercholesterolemia Market.
Hypercholesterolemia Pipeline Market Barriers
• However, high cost associated with the treatment, side effects associated with the disease and other factors are creating obstacles in the Hypercholesterolemia Market growth.
Scope of Hypercholesterolemia Pipeline Drug Insight
• Coverage: Global
• Key Hypercholesterolemia Companies: EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, Inc, Vaxxinity, Inc, Arrowhead Pharmaceuticals, Merck Sharp & Dohme LLC, Haisco Pharmaceutical Group Co., Ltd., Akeso Biopharma, Addpharma Inc., Jiangsu HengRui Medicine Co., Ltd., and others
• Key Hypercholesterolemia Therapies: EPIC-221, AMTX 100, Research programme: epigenetic editors, VERVE-101, VXX-401, ARO-ANG 3, MK-0616, HSK31679, Ebronucimab, AD-221, SHR-1209, and others
• Hypercholesterolemia Therapeutic Assessment: Hypercholesterolemia current marketed and Hypercholesterolemia emerging therapies
• Hypercholesterolemia Market Dynamics: Hypercholesterolemia market drivers and Hypercholesterolemia market barriers
Request for Sample PDF Report for Hypercholesterolemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Hypercholesterolemia Report Introduction
2. Hypercholesterolemia Executive Summary
3. Hypercholesterolemia Overview
4. Hypercholesterolemia- Analytical Perspective In-depth Commercial Assessment
5. Hypercholesterolemia Pipeline Therapeutics
6. Hypercholesterolemia Late Stage Products (Phase II/III)
7. Hypercholesterolemia Mid Stage Products (Phase II)
8. Hypercholesterolemia Early Stage Products (Phase I)
9. Hypercholesterolemia Preclinical Stage Products
10. Hypercholesterolemia Therapeutics Assessment
11. Hypercholesterolemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypercholesterolemia Key Companies
14. Hypercholesterolemia Key Products
15. Hypercholesterolemia Unmet Needs
16 . Hypercholesterolemia Market Drivers and Barriers
17. Hypercholesterolemia Future Perspectives and Conclusion
18. Hypercholesterolemia Analyst Views
19. Appendix
20. About DelveInsight
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypercholesterolemia Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight here
News-ID: 3879441 • Views: …
More Releases from DelveInsight Business Research
NLRP3 Protein Inhibitors Pipeline Expands With 20+ Companies Advancing 25+ Thera …
DelveInsight's latest publication, "NLRP3 Protein Inhibitors Pipeline Insight 2025," presents an in-depth evaluation of more than 20 companies and 25 investigational therapies advancing within the NLRP3 Protein Inhibitors development landscape. The report features detailed profiles of both clinical- and preclinical-stage candidates, along with an assessment of therapeutic approaches by product category, development phase, route of administration, and molecule type. Additionally, the analysis highlights inactive or discontinued programs in this domain.
Explore…
Global Clostridium Difficile Infections Pipeline Expands With 20+ Companies Adva …
DelveInsight's report, "Clostridium Difficile Infections Pipeline Insight, 2025," delivers an extensive overview of the current clinical development status and future growth opportunities within the CDI market.
The report offers a comprehensive commercial and clinical analysis of pipeline therapies, spanning from preclinical stages to marketed products. It includes detailed drug profiles covering mechanisms of action, clinical data, regulatory milestones, and product development updates such as technological innovations, collaborations, mergers and acquisitions, funding…
Global Urticaria Pipeline Expands With 20+ Companies Advancing 25+ Therapies, Re …
DelveInsight's "Urticaria Pipeline Insight, 2025" report provides an in-depth overview of the current landscape of clinical development and future growth potential within the Urticaria market.
The report delivers a comprehensive commercial and clinical analysis of pipeline therapies, spanning preclinical research to marketed products. It offers detailed drug profiles covering mechanisms of action, clinical study updates, regulatory milestones, and product development activities, including technology platforms, partnerships, collaborations, acquisitions, funding, designations, and other…
Global Neurofibromatosis Type 2 Pipeline Expands With 5+ Companies Advancing 5+ …
According to DelveInsight's analysis, the global Neurofibromatosis Type 2 (NF2) pipeline consists of more than five leading companies actively advancing over five therapeutic candidates. The assessment includes a comprehensive review of ongoing clinical trials, therapy mechanisms, routes of administration, and recent development activities.
DelveInsight's "Neurofibromatosis Type 2 Pipeline Insight, 2025" report delivers an extensive overview of the current clinical landscape and future growth potential across the Neurofibromatosis Type 2 market. The…
More Releases for Hypercholesterolemia
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Hypercholesterolemia Treatment Market Reviews Analysis Report 2024
Hypercholesterolemia Treatment Market to reach over USD 36.37 billion by the year 2031 - Exclusive Report by InsightAce Analytic
According to a new report by InsightAce Analytic, the "Hypercholesterolemia Treatment Market" in terms of revenue was estimated to be worth $27.9 billion in 2023 and is poised to reach $36.37 billion by 2031, growing at a CAGR of 3.43% from 2024 to 2031.
Get a free Sample copy of the…
Hypercholesterolemia Treatment Market: Transforming Lives: Impact of Hypercholes …
Newark, New Castle, USA: The "Hypercholesterolemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypercholesterolemia Treatment Market: https://www.growthplusreports.com/report/hypercholesterolemia-treatment-market/8571
This latest report researches the industry structure, sales, revenue,…
Hypercholesterolemia Treatment Market Insights, Forecast to 2031
The report extensively examines the global Hypercholesterolemia Treatment market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hypercholesterolemia Treatment . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Hypercholesterolemia Market Global Analysis & 2023 Forecast Report
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
